Want to see PHBID full AI Analyst Report?
PHBID Stock Chart & Stats
$1.00
$0.00(0.00%)
At close: 4:00 PM EST
$1.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.24 - $1.20
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$117.53K
Enterprise Value$722.72K
Total Cash (Recent Filing)$721.00
Total Debt (Recent Filing)$355.59K
Price to Earnings (P/E)―
Beta1.27
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding345,673
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-0.25
Price to Sales (P/S)277.91
P/FCF Ratio-28.48
Enterprise Value/Market Cap6.15
Enterprise Value/Revenue302.65
Enterprise Value/Gross Profit-1.81K
Enterprise Value/Ebitda1.66
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Reduced Operating Cash BurnThe sharp reduction in operating cash burn is a constructive change in financial performance. Although cash generation remains negative and does not yet support self-funding operations, continued improvement could reduce near-term financing pressure if sustained.
Positive Reported Net IncomePositive net income provides a limited earnings improvement in the latest period. However, because operating profitability remained deeply negative, this benefit appears dependent on non-operating items and requires sustained core earnings before becoming durable.
Prior-Year Gross ProfitThe positive gross profit recorded in 2024 shows that the business has previously generated some gross margin from its activities. This offers a potential operating base, but the reversal to a gross loss in 2025 indicates that the benefit is not currently sustainable.
Bears Say
Minimal And Declining RevenueThe extremely small and declining revenue base indicates limited commercial scale and weak market traction. Such low sales provide little coverage for fixed costs, constrain reinvestment capacity, and make a durable path to operating profitability difficult.
Severely Stressed Balance SheetDeeply negative equity, minimal assets, and material debt create substantial solvency and financial-flexibility risks. The company may require restructuring or external funding to continue, while its limited asset base provides little protection for creditors or shareholders.
Persistent Negative Cash GenerationPersistent negative operating and free cash flow shows that the business has not demonstrated a self-funding operating model. Even with lower recent burn, continued cash consumption can increase dependence on financing and restrict investment in products or growth.
PHBID FAQ
What was Pharmagreen Biotech’s price range in the past 12 months?
Pharmagreen Biotech lowest stock price was $0.24 and its highest was $1.20 in the past 12 months.
What is Pharmagreen Biotech’s market cap?
Pharmagreen Biotech’s market cap is $117.53K.
When is Pharmagreen Biotech’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Pharmagreen Biotech’s earnings last quarter?
Currently, no data Available
Is Pharmagreen Biotech overvalued?
According to Wall Street analysts Pharmagreen Biotech’s price is currently Overvalued.
Does Pharmagreen Biotech pay dividends?
Pharmagreen Biotech does not currently pay dividends.
What is Pharmagreen Biotech’s EPS estimate?
Pharmagreen Biotech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pharmagreen Biotech have?
Pharmagreen Biotech has 345,673 shares outstanding.
What happened to Pharmagreen Biotech’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Pharmagreen Biotech?
Currently, no hedge funds are holding shares in PHBID
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pharmagreen Biotech
Pharmagreen Biotech Inc. is a biotechnology solutions provider primarily engaged in cultivating young plant stock for the medical cannabis and CBD hemp industries. Established in 2007, the company operates from its base in Coquitlam, Canada.